



PRESS RELEASE
For Immediate Dissemination

**OPSENS TO HOST SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS CONFERENCE CALL ON
THURSDAY APRIL 13, 2023**

Conference call to be conducted at 11:00 am ET

Quebec City, Quebec, April 6, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, will report financial results for its second quarter of fiscal year 2023, ended February 28, 2023, on Thursday, April 13, 2023, before the open of the market. The Company has scheduled a conference call the same day, at 11:00 am ET, to review the results.

Interested parties can access the conference call by dialing 1-833-756-0865 or 1-412-317-5754 or can listen via a live webcast, from the link available in the Investors section of the Company’s website at <https://opsens.com/investors/> or at <https://app.webinar.net/Xz9d83makB1>, 5 to 10 minutes before the beginning of the conference call.

A replay will be available after the call, in the Investors section of the Company’s website at <https://opsens.com/investors/>.

About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of 200,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, United Kingdom, Japan, and Canada.

OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.

The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

For further information, please contact: Louis Laflamme, CPA, Chief Executive Officer, 418.781.0333
John Hannigan, FCA, Chief Financial Officer, 418.781.0333